Impax Begins Shipment Of Authorized Generic Renvela

(RTTNews) - Impax Laboratories Inc (IPXL) said Wednesday it is commencing shipment of authorized generic Renvela(sevelamer carbonate 800 mg tablets), through Global Pharmaceuticals, Impax's generics division.

Renvela is indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

Under the terms of a settlement agreement, Genzyme, a part of Sanofi (SNY), agreed to grant Impax a license to sell an allotment of a specified number of bottles of an authorized generic version of Renvela tablets commencing on April 16.

Impax continues to pursue approval of its pending Abbreviated New Drug Application for generic Renvela with the U.S. Food and Drug Administration.

According to IMS Health (NSP), U.S. sales of Renvela Tablets, 800 mg, were about $907 million for the 12 months ended February 2014.